Firivumab

Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3].

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

IC50: 0.1-1.3 μg/mL (H1N1), 0.78 μg/mL (H2N2), 0.48-0.65 μg/mL (H5N1), 4.69 μg/mL (H6N1), 4.69 μg/mL (H6N2), 2.34 μg/mL (H8N4), 1.3 μg/mL (H8N8), 2.08 μg/mL (H9N2) and 20.83 μg/mL (H12N7)[1]

Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 治疗组中对 H1N1 病毒显示 100% 的保护，在 7.5 mg/kg 治疗组中显示 70% 的保护[1]。 Firivumab (添加 7.5 mg/kg CT120 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护[1]。 Animal Model: Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)[1] Dosage: 7.5, 15, 30 mg/kg Administration: IP; Twenty-four hours post-infection Result: Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection.

[1]. Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172.  

[2]. John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463.  

[3]. Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.